RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2025 financial results on November 5, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to disc ...

Core Insights - ADMA Biologics reported a strong financial performance in Q1 2025, with total revenue of $114.8 million, representing a 40% year-over-year increase, and adjusted total revenue of $118.6 million, indicating approximately 45% growth when excluding one-time product withdrawals [1][9] - The company achieved a GAAP net income of $26.9 million, a 51% increase year-over-year, and an adjusted net income of $33.3 million, reflecting an 87% year-over-year growth [1][11] - Adjusted EBITDA for the quarter was $47.9 million, marking an 81% increase compared to the same period last year [1][12] Financial Performance - Total cash and receivables grew to approximately $171 million, providing a strong liquidity position [1][3] - The gross profit for Q1 2025 was $61.1 million, translating to a gross margin of 53.2%, up from 47.8% in Q1 2024 [10] - The company has increased its total revenue guidance for FY 2025 to more than $500 million and for FY 2026 to more than $625 million [1][7] Strategic Developments - The FDA approved a yield enhancement production process, expected to increase production output by 20% from the same starting plasma volume, which is anticipated to support revenue growth and margin expansion [1][3] - ADMA has authorized a $500 million share repurchase program, representing approximately 8% of its current market capitalization, aimed at enhancing stockholder value [1][8] - A debt reorganization has reduced ADMA's cost of debt capital by 1.1%, further strengthening its financial position [1][3] Market Position and Outlook - The company expects total annual revenues to exceed $1.1 billion by 2030, with significant earnings growth anticipated from current margin levels [2][7] - ADMA's U.S.-based manufacturing and supply chain provide insulation from geopolitical and global trade challenges, positioning the company favorably against multinational competitors [3][7] - The demand for ASCENIV, one of ADMA's key products, continues to trend towards record highs, with expectations for increased market penetration and new patient starts [4][7]

Core Viewpoint - ADMA Biologics, Inc. is set to report its first quarter 2025 financial results on May 7, 2025, and will host a conference call to discuss these results and other company updates [1]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB® [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].

Core Insights - ADMA Biologics, Inc. has received U.S. FDA approval for an innovative yield enhancement production process, which is expected to increase production yields by approximately 20% from the same starting plasma volume [1][2] - This approval is anticipated to significantly accelerate the company's revenue and earnings trajectory starting in late 2025 and continuing into 2026 and beyond [2] - ADMA is the first U.S. producer of plasma-derived products to achieve regulatory approval for this innovative process, showcasing its leadership in modernizing plasma fractionation [2] Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently markets three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB® [3] - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, demonstrating its commitment to product and process innovation [3] Production and R&D Capabilities - The innovative yield enhancement process is expected to benefit both ASCENIV and BIVIGAM, enhancing production output capacity [1] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, that collects source plasma for its products [3] - The company holds numerous U.S. and foreign patents related to its products and product candidates, reinforcing its competitive position in the market [3]

Core Viewpoint - ADMA Biologics, Inc. emphasizes its strategic advantage due to fully U.S.-based manufacturing and supply chain operations, which are insulated from recent tariffs on foreign goods [1][2]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®, targeting immune deficiencies and hepatitis B [3]. - ADMA operates an FDA-licensed facility in Boca Raton, Florida, for the production of its immune globulin products and also runs FDA-approved source plasma collection through its subsidiary, ADMA BioCenters [3]. Group 2: Strategic Positioning - The company asserts that the tariffs on foreign goods will not affect its supply chain or production operations due to its fully integrated U.S.-based supply chain [2]. - ADMA's operational model ensures enhanced supply chain robustness, resilience, and regulatory compliance, aligning with federal and private sector preferences for U.S.-made products [2]. - By maintaining complete operational control within the U.S., ADMA is positioned to leverage national economic incentives and provide reliable, high-quality offerings to its domestic customers [2].